Glucose-dependent insulinotropic peptide for use as an osteotropic hormone

• US 6,410,508 B1
• Filed: 10/07/1999
• Issued: 06/25/2002
• Est. Priority Date: 10/07/1998
• Status: Expired due to Fees

• Current Assignee: Medical College of Georgia Research Institute Inc (University System of Georgia)
• Original Assignee: Medical College of Georgia Research Institute Inc (University System of Georgia)
• Inventors: Bollag, Roni J., Isales, Carlos M., Rasmussen, Howard
• Primary Examiner(s): Priebe, Scott D.
• Assistant Examiner(s): Kaushal, Sumesh
• Application Number:
  US09/414,189
• Time in Patent Office: 992 Days
• Field of Search: 514/2, 514/3, 514/12, 514/866, 530/303, 530/308, 424/184.1, 424/198.1, 435/69.1, 435/69.4, 435/325, 435/243
• US Class Current: 514/16.7
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: C07K 14/605 Glucagons

Abstract

The examples demonstrate that GIP receptor mRNA and protein are present in normal bone and osteoblastic-like cell lines, and that high-affinity receptors for GIP can be demonstrated by ¹²⁵I GIP binding studies. When applied to osteoblast-like cells (SaOS2), GIP stimulated an increase in cellular cAMP content and in intracellular calcium, with both responses being dose dependent. Moreover, administration of GIP results in elevated expression of collagen type I mRNA as well as an increase in alkaline phosphatase activity. Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblastic like cells and that GIP modulates the function of these cells. GIP has anabolic actions on remodeling bone, increasing vertebral bone density in a rat model of osteoporosis. GIP at 10 nM inhibits PTH-induced bone resorption in a fetal long bone assay and stimulates the synthesis of type 1 collagen mRNA. Transgenic mice overexpressing GIP have increased bone density compared to same age controls. GIP or analoges thereof can therefore be used as a therapeutic to inhibit bone resorption and to maintain or increase bone density. GIP antagonists, compounds which block binding to the GIP receptor, can be used to decrease bone density.

Claims

1. A method for maintaining or increasing bone density or formation in a female subject having reduced bone mineralization associated with reduced ovarian function comprising administration of an effective amount of Glucose-Dependent Insulinotropic Peptide (GIP) as a pharmaceutically acceptable formulation to said subject, wherein said effective amount comprises sufficient GIP polypeptide to maintain or increase bone density in said subject.

2. The method of claim 1, wherein said reduced ovarian function is associated with menopause.

3. The method of claim 1, wherein said GIP polypeptide is administered intravenously.

4. The method of claim 1, wherein said GIP comprises GIP polypeptide expressed from recombinant GIP cDNA and isolated from cultured cells.

5. The method of claim 1, further comprising modifying said GIP polypeptide to increase the pharmacological half-life of the GIP.

6. A composition for maintaining or increasing bone density or formation in a female subject having reduced bone mineralization associated with reduced ovarian function comprsing an effective dose of Glucose-Dependent Insulinotropic Peptide (GIP) in a pharmaceutically acceptable carrier, wherein said effective dose comprises sufficient GIP polypeptide to increase serum GIP concentration by at least 0.001 nM to 100 μ

M.

7. The composition of claim 6, wherein said effective dose comprises from 0.0001 to 100 mg GIP per kg body weight of said subject.

8. The composition of claim 6, wherein said effective dose comprises from 0.001 to 5 mg GIP per kg body weight of said subject.

9. The composition of claim 6, wherein said effective dose comprises from 0.01 to 0.25 mg GIP per kg body weight of said subject.

10. The composition of claim 6, wherein said GIP comprises GIP polypeptide expressed from recombinant GIP cDNA and isolated from cultured cells.

11. The composition of claim 6, wherein said GIP polypeptide is modified to increase the pharmacological half-life of the GIP.

12. The composition of claim 6, wherein said pharmaceutical carrier is suitable for intravenous administration of GIP.

13. The composition of claim 6, wherein said reduced ovarian function is associated with menopause.